Accro Bioscience Limited

Privately held: no public share price

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
TYK2Small molecule
Psoriasis

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

20 May 2025Topline resultAC-201Phase 2 (NCT06972888) of AC-201 in moderate-to-severe plaque psoriasis met its primary endpoint (PASI-75 at week 12) at all three doses
Accropeutics · Source ↗

Financial reports

No financial reports recorded.